United States securities and exchange commission logo





                      April 23, 2021

       Thomas Striepe
       Chief Financial Officer
       SANGUI BIOTECH INTERNATIONAL INC
       Bleichenbr  cke 9, 20354
       Hamburg, Germany

                                                        Re: SANGUI BIOTECH
INTERNATIONAL INC
                                                            Form 10-K for the
Fiscal Year Ended June 30, 2020
                                                            Filed September 30,
2020
                                                            File No: 000-29233

       Dear Mr. Striepe:

               We issued comments to you on the above captioned filing on April
1, 2021. As of the
       date of this letter, these comments remain outstanding and unresolved.
We expect you to
       provide a complete, substantive response to these comments by May 7,
2021.

               If you do not respond, we will, consistent with our obligations
under the federal securities
       laws, decide how we will seek to resolve material outstanding comments
and complete our
       review of your filing and your disclosure. Among other things, we may
decide to release
       publicly, through the agency's EDGAR system, all correspondence,
including this letter, relating
       to the review of your filings, consistent with the staff's decision to
publicly release comment and
       response letters relating to disclosure filings it has reviewed.

              Please contact Tracey McKoy, Staff Accountant, at (202)551-3772
or, Nudrat Salik, Staff
       Accountant, at (202)551-3692) or, Terence O'Brien, Accounting Branch
Chief, at (202)551-3355
       with any questions




                      Sincerely,


                      Division of Corporation Finance

                      Office of Life Sciences